Special Issue

Nano-Bio Interface Toxicity and Applications 2.0

Message from the Guest Editors

The fate of nanomaterials in a biological environment for their applications in medicine is currently a hot topic due to the formation of protein corona, which limits their use in biomedicine. Therefore, functionalisation of inorganic/organic nanoparticles with biomolecules such as oligonucleotides, antibodies, protein and disease specific biomarkers is a topical area of research receiving a huge amount of interest from experts in biomedicine. In this Special Issue, we welcome research articles, communications and reviews on application of functional nanomaterials in biomedicine by exploring the formation of protein corona, in the nano-bio interface, a range of biomolecules conjugated nanoparticles and their toxicity.

Guest Editors

Prof. Dr. Nguyen T.K. Thanh

Biophysics Group, Department of Physics and Astronomy, University College London, London WC1E 6BT, UK

Dr. Tapas Sen

School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UK

Deadline for manuscript submissions

closed (31 May 2022)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/89921

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).